# An immune-mediated effect of the antibiotic cefiderocol on LPS-induced acute lung injury

## TL;DR

This study shows that the antibiotic cefiderocol can reduce lung injury caused by inflammation and cell death, acting like a protective agent in a mouse model.

## Contribution

The novel contribution is the discovery of cefiderocol's immune-modulatory and anti-ferroptotic effects in acute lung injury.

## Key findings

- Cefiderocol pretreatment reduced lung tissue damage and pro-inflammatory cytokines in LPS-induced ALI.
- The drug's protective effect was comparable to ferrostatin-1, a known ferroptosis inhibitor.
- Cefiderocol's efficacy suggests a role in modulating ferroptosis and inflammation in lung injury.

## Abstract

This study examines the immune-modulatory effects of cefiderocol in a murine model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Cefiderocol pretreatment significantly reduced lung tissue damage, lowered pro-inflammatory cytokines, and decreased ferroptosis markers. Its protective effect was comparable to that of the ferroptosis inhibitor ferrostatin-1, while cefepime showed limited efficacy. These findings suggest that cefiderocol has an immuno-mediated role in LPS-induced ALI, potentially by modulating ferroptosis and inflammation, warranting further investigation for sepsis-related complications.

This study examines the immune-modulatory effects of cefiderocol in a murine model of LPS-induced acute lung injury (ALI). Cefiderocol pretreatment significantly reduced lung tissue damage, lowered pro-inflammatory cytokines, and decreased ferroptosis markers. Its protective effect was comparable to that of the ferroptosis inhibitor ferrostatin-1, while cefepime showed limited efficacy. These findings suggest that cefiderocol has an immuno-mediated role in LPS-induced ALI, potentially by modulating ferroptosis and inflammation, warranting further investigation for sepsis-related complications.